Showing 5301-5310 of 5771 results for "".
- Spectralis High Magnification Module Receives CE Markinghttps://modernod.com/news/spectralis-high-magnification-module-receives-ce-marking/2476331/Heidelberg Engineering announced CE Mark approval of the Spectralis High Magnification Module. With the addition of a lens and software upgrade, the new module enables visualization of the ocular
- Clinical Trials Planned for Iris-Recognition-Based Patient Identification Softwarehttps://modernod.com/news/clinical-trials-planned-for-iris-recognition-based-patient-identification-software/2476333/Patientory and UK-based IrisGuard announced a collaboration to combine leading iris biometric technology and healthcare focused PTOYNet blockchain network for enhanced security measures. The HIPAA-compliant Patientory App, which already adheres to strict security requirements, will utilize the be
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- Bausch Health Reduces Debt By Additional $100 Millionhttps://modernod.com/news/bausch-health-reduces-debt-by-additional-100-million/2476341/Bausch Health Companies, the parent company of Bausch + Lomb, announced it has paid down an additional $100 million of its senior secured term loans using cash generated from operations. “As Bausch Health pivots to offense in 2019, we continue to remain
- Lutronic Vision Initiates Preclinical Trial of R:GEN Laser for the Treatment of Dry AMDhttps://modernod.com/news/lutronic-vision-initiates-preclinical-trial-of-rgen-laser-for-the-treatment-of-dry-amd/2476343/Lutronic Vision announced that it has initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). This study has been initiated at the University of Southern California with Stan Louie, PharmD, Pr
- Study: Scleral Lenses Coated with Tangible Hydra-PEG Improve Dry Eye Symptoms, Comforthttps://modernod.com/news/study-scleral-lenses-coated-with-tangible-hydra-peg-improve-dry-eye-symptoms-comfort/2476344/Tangible Science announced that a
- China’s NMPA Accepts NDA for IBI-305, a Biosimilar Product Candidate of Bevacizumab (Avastin)https://modernod.com/news/chinas-nmpa-accepts-nda-for-ibi-305-a-biosimilar-product-candidate-of-bevacizumab-avastin/2479596/Innovent Biologics announced that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for a biosimilar product candidate of bevacizumab (Avastin). This NDA by Innovent is the third that has been accepted by the NMPA following Tyvyt (sintilimab injectio
- Ocutech Starts Roll-Out of New VES Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-starts-national-roll-out-of-new-ves-falcon-autofocus-bioptic-telescope/2479599/Ocutech announced the release of the new VES Falcon Autofocus Bioptic Telescope to low vision specialists internationally. The Falcon is the next generation of the world’s only autofocusing bioptic telescope for the visually impaired, according to Ocutech. The Falcon’s advanced technology
- Nicox Establishes High-Profile Glaucoma Clinical Advisory Boardhttps://modernod.com/news/nicox-establishes-high-profile-glaucoma-clinical-advisory-board/2479601/Nicox SA announced the formation of Nicox Glaucoma Clinical Advisory Board, composed of key clinical investigators and opinion leaders in the field, to support and guide the development of its innovative NO-donating compounds as potential IOP-lowering drugs.
- EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directorshttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-guyer-md-to-board-of-directors/2479602/EyePoint Pharmaceuticals announced the appointment of David Guyer, MD, to the company’s Board of Directors. He will also serve on the company’s Science Committee. Dr. Guyer has led several public and private biotechnology companies focused on ocular diseases, and has held leadership positi